目的 了解南方醫(yī)科大學(xué)附屬東莞醫(yī)院莫西沙星藥品不良反應(yīng)（ADR）的特點及有關(guān)因素，為莫西沙星的臨床合理用藥治療提供一定的參考。方法 對南方醫(yī)科大學(xué)附屬東莞醫(yī)院2016—2019年醫(yī)院電子病歷系統(tǒng)收錄的莫西沙星的藥品不良反應(yīng)病例進行回顧性的分析總結(jié)，分析不良反應(yīng)的規(guī)律及其相關(guān)因素。結(jié)果 共收集5 986例莫西沙星藥物使用病例，關(guān)于不良反應(yīng)的有132例；其中一般ADR出現(xiàn)119例（90.15%），嚴(yán)重ADR出現(xiàn)13例（9.85%）；ADR主要發(fā)生在36～59歲和≥60歲的中老年患者；靜脈給藥的有129例（97.73%），口服給藥的有3例（2.27%）。ADR涵蓋了皮膚及其附件系統(tǒng)、神經(jīng)系統(tǒng)、消化系統(tǒng)、心血管系統(tǒng)；發(fā)生ADR后，患者停藥處理后均痊愈或好轉(zhuǎn)，無出現(xiàn)后遺癥患者。結(jié)論 莫西沙星的ADR發(fā)生率較少，嚴(yán)重ADR發(fā)生率較低，但存在著新的ADR，臨床醫(yī)護人員應(yīng)該有著足夠的重視，確保安全、合理地使用該藥。

Objective To understand the characteristics and related factors of adverse drug reactions (ADR) of moxifloxacin in Dongguan Hospital affiliated to Southern Medical University, to provide some reference for the clinical rational drug use of moxifloxacin. Methods The adverse drug reactions (ADR) cases of moxifloxacin recorded in the electronic medical record system of Dongguan Hospital affiliated to Southern Medical University from 2016 to 2019 were retrospectively analyzed and summarized, and the rule of adr and its relationship with related factors were analyzed Results A total of 5 986 cases of moxifloxacin use were collected, including 132 cases of adverse reactions. There were 119 cases (90.15%) of general ADR, and 13 cases (9.85%) of severe ADR. Adverse reactions mainly occurred in middle-aged and elderly patients aged 36 — 59 years and ≥ 60 years old. 129 cases (97.73%) were given intravenously, and 3 cases (2.27%) were given orally. Adverse reactions include skin and its accessory system, nervous system, digestive system and cardiovascular system. After adverse reactions occurred, all patients were cured or improved after drug withdrawal, and no sequelae occurred. Conclusion The incidence of moxifloxacin adverse reactions was relatively low, and the incidence of severe ADR was relatively low. But there are new adverse reactions. The clinical medical staff should still have enough attention, to ensure the safe and reasonable use of this drug.

R978.1

廣東省醫(yī)學(xué)科研基金資助項目（B2020086）；廣東省醫(yī)院藥學(xué)研究基金（澳美基金）資助項目（2021A08）